Viracta Therapeutics, Inc.
We are preparing, please wait
Undervalued or Overvalued?
Unfortunately, this content is only accessible to registered users
Login to ContinueKey stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Market Cap
$24.19 M
Change
$0.01
EPS
-$1.23
P/E Growth
-0.5
2533 South Coast Highway 101, Cardiff-by-the-Sea, CA, 92007
Sector:
Industry:
Fiscal Year-end
December
Revenue
$0
Net Income
$-51,058,000
2023 Sales Growth
0.00%
Viracta Therapeutics, Inc.'s CEO, Mr. Mark Andrew Rothera
Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket trial for the treatment of various relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. The company's development pipeline includes vecabrutinib, a clinical-stage non-covalent ITK/BTK inhibitor and VRx-510 (formerly SNS-510), a preclinical-stage PDK-1 inhibitor. It is evaluating development and collaboration opportunities for vecabrutinib in combination with chimeric antigen receptor T-cell therapies and VRx-510 in various oncology indications. The company was formerly known as Sunesis Pharmaceuticals, Inc. to Viracta Therapeutics, Inc. in February 25, 2021. Viracta Therapeutics, Inc. was incorporated in 1998 and is headquartered in Cardiff-by-the-Sea, California.
An income statement known as a profit and loss statement, is a financial report that summarizes a company's revenues, expenses, gains, and losses over a specific period. It provides insight into a company's operational efficiency and profitability, helping investors and stakeholders assess financial performance and make informed decisions.
The Financials Balance Sheet report provides a clear and concise visual summary of a company’s financial standing through interactive charts. This section highlights key components such as assets, liabilities, and equity, offering investors an at-a-glance understanding of the company's financial health. By showcasing these critical metrics in an easy-to-digest format, the report enables stakeholders to evaluate the company’s stability, operational efficiency, and capital structure, fostering more informed investment decisions.
The Financials Cash Flow report uses charts to provide a clear breakdown of a company’s cash flow across operating, investing, and financing activities. This visualization helps investors quickly assess how the company generates, spends, and manages cash, offering valuable insights into its liquidity and financial efficiency.
Market Benchmark Score
Market Score: Aggregate the average P/E ratio of all companies in the market.
Industry Score: Aggregate the average P/E ratio of all companies in the same industry.
ASSETS
$56.69 M
LIABILITIES
$38.37 M
DEBT Equity Ratio
-2.56
Operating Cash Flow
$-39,892,000
The latest Technical Analysis Summary on Stocks.News offers insights into market trends using key Technical Indicators like RSI and MACD, alongside Moving Averages such as the 50-day and 200-day. The analysis identifies buy and sell signals through bullish or bearish crossovers, helping investors make informed trading decisions.
Today's price of Viracta Therapeutics, Inc. is $0.20 — it has increased by +4.95%
Yes, you can track Viracta Therapeutics, Inc.'s financials in yearly and quarterly reports directly on Stocks.News.
Watch the Viracta Therapeutics, Inc. chart and read a more detailed Viracta Therapeutics, Inc. stock forecast to see what analysts suggest you do with its shares.
The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by Viracta Therapeutics, Inc. stock ticker.
Like other stocks, VIRX shares are sold on stock exchanges such as NASDAQ The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.
Viracta Therapeutics, Inc. measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in Viracta Therapeutics, Inc.’s financial statements.
